1. Inicio
  2. Publicaciones
  3. Hemodynamic effects of HPMA copolymer based doxorubicin conjugate: A randomized controlled and comparative spectral study in conscious rats

Hemodynamic effects of HPMA copolymer based doxorubicin conjugate: A randomized controlled and comparative spectral study in conscious rats

Fecha de publicación:

Autores de CIPF

Participantes ajenos a CIPF

  • Cheah, HY
  • Sarenac, O
  • Vasic, M
  • Lozic, M
  • Glumac, S
  • Hoe, SZ
  • Hindmarch, CCT
  • Murphy, D
  • Kiew, LV
  • Lee, HB
  • Chung, LY
  • Japundzic-Zigon, N

Grupos de Investigación

Abstract

Conjugation of Doxorubicin (DOX) to N-(2-hydroxypropyl) methylacrylamide copolymer (HPMA) has significantly reduced the DOX-associated cardiotoxicity. However, the reports on the impact of HPMA-DOX conjugates on the cardiovascular system such as blood pressure (BP) and heart rate (HR) were in restrained animals using tail cuff and/or other methods that lacked the resolution and sensitivity. Herein, we employed radiotelemetric-spectral-echocardiography approach to further understand the in vivo cardiovascular hemodynamics and variability post administration of free DOX and HPMA-DOX. Rats implanted with radio-telemetry device were administered intravenously with DOX (5mg/kg), HPMA-DOX (5mg DOX equivalent/kg) and HPMA copolymer and subjected to continuous cardiovascular monitoring and echocardiography for 140 days. We found that DOX-treated rats had ruffled fur, reduced body weight (BW) and a low survival rate. Although BP and HR were normal, spectral analysis indicated that their BP and HR variabilities were reduced. All rats exhibited typical signs of cardiotoxicity at histopathology. In contrast, HPMA-DOX rats gained weight over time and survived. Although BP, HR and related variabilities were unaffected, the left ventricular end diastolic volume (EDV) of these rats, as well as of the HPMA copolymer-treated rats, was found increased at the end of observation period. Additionally, HPMA copolymer caused microscopic injury of the heart tissue. All of these suggest the necessity of caution when employing HPMA as carrier for prolonged drug delivery. The current study also indicates the potential of radiotelemetric-spectral-echocardiography approach for improved preclinical cardiovascular risk assessment of polymer-drug conjugate and other nano-sized-drug constructs.

Datos de la publicación

ISSN/ISSNe:
1743-5390, 1743-5404

Nanotoxicology  TAYLOR & FRANCIS LTD

Tipo:
Article
Páginas:
210-222
PubMed:
28098511

Citas Recibidas en Web of Science: 21

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Nanomaterials; polymer carriers; telemetry; echocardiography; cardiotoxicity

Proyectos asociados

Towards the design of Personalised Polymer-based Combiantion Nanomedicines for Advanced Stage Breast Cancer Patients

Investigador Principal: MARIA JESUS VICENT DOCON

COMMISSION OF EUROPEAN COMMUNITIES . 2015

Polímeros Terapéuticos diseñados para cruzar la Barrera Hematoencefálica para el tratamiento de desordenes neurodegenerativos-Explorando la Ruta Intranasal.

Investigador Principal: MARIA JESUS VICENT DOCON

MINISTERIO DE ECON. Y COMPET. . 2016

Desarrollo de un estrategia para la prevención miocárdica del daño inducido por reperfusión basada en el uso de catéteres y polímeros teraéuticos de nueva generación Premicat

Investigador Principal: MARIA JESUS VICENT DOCON

INSTITUTO DE SALUD CARLOS III . 2016

Compartir